Sort
82,697 grants matching “vaccine development”
IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT
$814,531Brigham And Women'S Hospital · P01 · FY2002 · AI
Administrative Core
$814,513Jason A Mendoza · Fred Hutchinson Cancer Center · U19 · FY2024 · MD
Development of an Adhesin-Toxoid Chimera Vaccine for Enterotoxigenic E. coli
$814,422Stephen J Savarino · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2010 · AI
Developing Durable, Env-Boosted CAR T Cells for HIV Cure
$814,373Christopher W Peterson · Fred Hutchinson Cancer Center · R01 · FY2025 · AI
International Training in AIDS-Related Epidemiology
$814,329Myron E Essex · Harvard School Of Public Health · D43 · FY2008 · TW
Basic and clinical studies in immune function and metabolism
$814,165Peter McGuire · National Human Genome Research Institute · ZIA · FY2013 · HG
Impact of the COVID-19 Pandemic on Patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias
$814,164John Hsu · Massachusetts General Hospital · U01 · FY2024 · AG
Immunologic and Metabolic Profiles of T cells that control diverse HCV infections
$814,143Andrea L Cox · Johns Hopkins University · U19 · FY2022 · AI
Expansion of SARS-CoV-2 Testing Supplement, Chicago Clinical Trials Unit
$814,136Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2020 · AI
Infant Immunoprophylaxis against a Primate Lentivirus
$814,028Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · R37 · FY2010 · AI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs
$814,022Lishan Su · University Of Maryland Baltimore · R01 · FY2022 · AI
Immune reconstitution following autologous and allogeneic stem cell transplant
$813,983Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2012 · CA
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIV
$813,950Rachel Lena Rutishauser · University Of California, San Francisco · R01 · FY2023 · AI
Immune Dysfunction in HIV+ Opioid Users
$813,855Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2021 · DA
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2022 · AI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2021 · AI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2023 · AI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2024 · AI
Antibody-based countermeasures against fentanyl and its analogues
$813,791Marco Pravetoni · University Of Minnesota · U01 · FY2020 · DA
Pathogenic determinants of the SIV envelope transmembrane cytoplasmic domain
$813,747James A Hoxie · University Of Pennsylvania · R01 · FY2012 · AI
Fogarty AIDS International Training and Research Program (AITRP)
$813,746Chris Beyrer · Johns Hopkins University · D43 · FY2008 · TW
Interrogating human anti-staphylococcal antibody responses for S. aureus vaccine insights
$813,730George Y Liu · University Of California, San Diego · R01 · FY2024 · AI
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
$813,635Xiangpeng Kong · New York University School Of Medicine · R01 · FY2019 · AI
IMMUNOBIOLOGY OF VARICELLA AND ZOSTER IN A PRIMATE MODEL
$813,576Ravi Mahalingam · University Of Colorado Denver · P01 · FY2015 · AG
Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia
$813,514Jodi K Craigo · Cytoagents, Inc. · R44 · FY2021 · AI